Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences, BioInvent Pen Broad Antibody R&D Collaboration

NEW YORK, March 14 - Oxford GlycoSciences and BioInvent International on Thursday said they are partnering for three years to identify, develop, manufacture, and commercialize therapeutic antibodies.
 
Terms of the agreement call for OGS to provide at least five target antigens per year, which it will identify and validate through its proteomics process. BioInvent, in turn, will apply its n-CoDeR phage display library to identify antibodies targeted to those antigens.

The companies will then select candidates to develop into therapeutic candidates, and BioInvent will manufacture all of the requisite pre-clinical and clinical materials.

Financial details of the deal were not disclosed. However, OGS said it will contribute research funding and will pay a technology access fee to BioInvent. Additionally, any antibody candidates that come out of the deal will be developed either jointly, in which case the costs of research and development and subsequent revenues will be equally split, or by OGS alone. 

The terms also said that BioInvent will be able to select at least one antibody candidate each year. OGS, on the other hand, will be responsible to research and develop all other candidates, for which BioInvent will receive undisclosed milestone and royalty payments. However, OGS will retain all commercial rights for these solely developed products. 

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.